
==== Front
Indian J Crit Care Med
Indian J Crit Care Med
IJCCM
Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine
0972-5229
1998-359X
Jaypee Brothers Medical Publishers

10.5005/jp-journals-10071-24642
Letter to the Editor
Analgo-sedation in Patients on Non-invasive Mechanical Ventilation: Need for Guideline Recommendation
Shrinath V 1https://orcid.org/0000-0001-7881-7115

Marwah Vikas 2https://orcid.org/0000-0002-7033-6090

Jyothis MC 3https://orcid.org/0000-0002-6517-9633

1 Department of Respiratory Medicine, INHS Asvini, Mumbai, Maharashtra, India
2,3 Department of Respiratory Medicine, Army Institute of Cardiothoracic Sciences, Pune, Maharashtra, India
Shrinath V, Department of Respiratory Medicine, INHS Asvini, Mumbai, Maharashtra, India, Phone: +91 7893257568, e-mail: drshrinathv@outlook.com
3 2024
29 2 2024
28 3 309310
Copyright © 2024; The Author(s).
2024
https://creativecommons.org/licenses/by-nc/4.0/ © The Author(s). 2024 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
How to cite this article

Shrinath V, Marwah V, Jyothis MC. Analgo-sedation in Patients on Non-invasive Mechanical Ventilation: Need for Guideline Recommendation. Indian J Crit Care Med 2024;28(3):309–310.

Keywords

Analgesia
ICU sedation
Noninvasive mechanical ventilation
==== Body
pmc Dear Editor,

We are writing this to bring attention to a grey area of critical care that warrants consideration and discussion—the unmet need for guideline recommendations regarding analgosedation in patients on noninvasive mechanical ventilation (NIV). The use of NIV has expanded significantly with increased evidence of its efficacy in acute respiratory failure. Noninvasive mechanical ventilation is now being used in intensive care and high-dependency units to manage patients with hypercapnic and hypoxemic respiratory failure. The success of NIV depends on proper patient selection and interface tolerance by the patient. The ideal patients who will benefit from NIV therapy are those with respiratory failure who have an intact sensorium without any severe facial deformity, facial burns, or fixed upper airway obstruction. Noninvasive mechanical ventilation interface intolerance on the other hand is multifactorial and is the leading cause of NIV failure. Noninvasive mechanical ventilation intolerance can be due to improper interface, ventilator setting, lack of humidification, excessive air leaks, delirium, anxiety, pain, pressure sores, and claustrophobia. Proper interface is the most important factor in NIV tolerance. A properly fitting interface reduces air leaks, and improves ventilator triggering, and patient ventilation.

A systematic approach must be taken to manage patients with NIV intolerance. Interface, humidification, and air leaks must be assessed and corrected first. Ventilator settings must be reviewed so that inspiratory sensitivity, cycling and rise time suit the underlying pathology and patient. The role of pharmacological therapy in the form of analgosedation arises when these non-pharmacological methods are exhausted and the patient's NIV intolerance is attributed to delirium or anxiety. Even with ever-increasing evidence on the use of NIV, the risk-benefit ratio of sedatives and analgesics for these patients is poorly studied and the choice of drugs remains controversial with absent guidelines. The ERS/ATS guidelines and ISCCM guidelines have not offered any recommendation on analgosedation for NIV.1,2 The BTS guidelines have recommended the use of sedative drugs in NIV with close monitoring in the ICU setting but have not offered any clarification on patient selection, drug selection, or drug dose.3

The use of analgosedation in NIV can have important patient benefits. It can reduce pain and anxiety whereby calming down the patient and improving ventilation. By reducing tachypnea and respiratory distress it can reduce ventilator-induced lung injury. Analgo-sedatives can modulate autonomic system response to stress and can improve sleep in patients on NIV therapy. There is good quality evidence that the use of analgosedation is associated with improved NIV tolerance and reduced risk of invasive mechanical ventilation.4,5 While the use of sedation or analgesia alone is beneficial, their combined use is associated with increased NIV failure.6 An ideal analgo-sedative drug should have a rapid onset and offset of action, minimal respiratory depression, wide therapeutic window, good reversibility, minimal impact on cognitive function, and should have predictive pharmacokinetics. Even though there are no ideal analgo-sedative drugs, the drugs which have been mostly studied in NIV patients include dexmedetomidine, remifentanil, midazolam, and propofol. The administration of these drugs should be closely monitored to attain a target sedation score like Ramsay score of 2–3, Richmond agitation and sedation scale (RASS) of -1–1, or sedation agitation scale (SAS) of 3–4.

Dexmedetomidine is the most studied drug for NIV sedation. Compared to other sedatives dexmedetomidine is associated with a reduced risk of intubation, shorter duration of NIV therapy, and reduced risk of delirium.7 Most studies with dexmedetomidine have used a continuous intravenous infusion rate of 0.2–0.7 μg/kg/hr with or without a loading dose of 1.0 μg/kg over 10 minutes. It has the advantage of providing good analgesia and sedation without respiratory depression. The most common adverse effects encountered are bradycardia and hypotension.

Though the amount of evidence is small, remifentanil is another drug that is as effective as dexmedetomidine in patients with NIV intolerance. There are no significant differences between the two drugs in terms of tracheostomy, in-hospital mortality, or ICU length of stay.8 It is given as an intravenous infusion of 0.05–0.12 μg/kg/hr. The advantage of the drug is that it is not affected by hepatic or renal dysfunction and is easy to titrate. Though midazolam, propofol, morphine, and haloperidol have been tried as analgo-sedatives in NIV patients dexmedetomidine and remifentanil are far superior.

In conclusion, it is high time that proper guidelines are laid out to identify patients on NIV therapy who will benefit from analgo-sedatives. The guidelines should cover the prerequisites before initiating therapy, the drug of choice, preferred dosing, and sedation goals that must be targeted.

Orcid

Shrinath V https://orcid.org/0000-0001-7881-7115

Vikas Marwah https://orcid.org/0000-0002-7033-6090

Jyothis MC https://orcid.org/0000-0002-6517-9633

Source of support: Nil

Conflict of interest: None
==== Refs
References

1. Rochwerg B Brochard L Elliott MW Hess D Hill NS Nava S et al. Official ERS/ATS clinical practice guidelines: Noninvasive ventilation for acute respiratory failure Eur Respir J 2017 50 2 1602426 10.1183/13993003.02426-2016 28860265
2. Gupta S Ramasubban S Dixit S Mishra R Zirpe KG Khilnani GC et al. ISCCM guidelines for the use of non-invasive ventilation in acute respiratory failure in adult ICUs Indian J Crit Care Med 2020 24 S1 S61 S81 10.5005/jp-journals-10071-G23186 32205957
3. Davidson AC Banham S Elliott M Kennedy D Gelder C Glossop A et al. BTS/ICS guideline for the ventilatory management of acute hypercapnic respiratory failure in adults Thorax 2016 71 Suppl 2 ii1 ii35 10.1136/thoraxjnl-2015-208209 26976648
4. Hadda V Bhakta P Karim HMR Piervincenzi E Šarc I Calandra C et al. Role of sedation and analgesia during non-invasive ventilation: Systematic review of recent evidence and recommendations Indian J Crit Care Med 2022 26 8 938 948 10.5005/jp-journals-10071-23950 36042773
5. Yang B Gao L Tong Z Sedation and analgesia strategies for non-invasive mechanical ventilation: A systematic review and meta-analysis Heart Lung 2024 63 42 50 10.1016/j.hrtlng.2023.09.005 37769542
6. Muriel A Peñuelas O Frutos-Vivar F Arroliga AC Abraira V Thille AW et al. Impact of sedation and analgesia during noninvasive positive pressure ventilation on outcome: A marginal structural model causal analysis Intensive Care Med 2015 41 9 1586 1600 10.1007/s00134-015-3854-6 25971392
7. Lewis K Piticaru J Chaudhuri D Basmaji J Fan E Møller MH et al. Safety and efficacy of dexmedetomidine in acutely ill adults requiring non-invasive ventilation Chest 2021 159 6 2274 2288 10.1016/j.chest.2020.12.052 33434496
8. Hao GW Luo JC Xue Y Ma GG Su Y Hou JY et al. Remifentanil versus dexmedetomidine for treatment of cardiac surgery patients with moderate to severe noninvasive ventilation intolerance (REDNIVIN): A prospective, cohort study J Thorac Dis 2020 12 10 5857 5868 10.21037/jtd-20-1678 33209418
